Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

CD47 and TIGIT double-target-point-based lung squamous cell carcinoma patient prognosis evaluation system and application thereof

A technology for prognostic assessment and squamous cell carcinoma of the lung, applied in the field of biomedicine, can solve the problems of lack of external validation and complicated methods

Pending Publication Date: 2022-06-28
CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although a variety of biomarkers have been found to be associated with the prognosis of lung squamous cell carcinoma patients, they have not been widely used in clinical practice due to the complexity of the method and the lack of external validation.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • CD47 and TIGIT double-target-point-based lung squamous cell carcinoma patient prognosis evaluation system and application thereof
  • CD47 and TIGIT double-target-point-based lung squamous cell carcinoma patient prognosis evaluation system and application thereof
  • CD47 and TIGIT double-target-point-based lung squamous cell carcinoma patient prognosis evaluation system and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] Example 1. Application of TIGIT and CD47 as markers in the prognosis evaluation of patients with lung squamous cell carcinoma

[0056] 1. The application of substances that detect the expression of TIGIT and CD47 at the RNA level in the prognosis evaluation of patients with lung squamous cell carcinoma

[0057] 1. Research objects and methods

[0058] The clinical information of 479 patients with lung squamous cell carcinoma LUSC who underwent surgery was extracted from The Cancer Genome Atlas (TCGA) database, including age, gender, stage, etc. The clinicopathological characteristics are shown in Table 1. Median age: 68 years old (39-85 years old), male: 353 cases (73.7%), stage: 234 cases (48.9%) of stage I; 156 cases (32.5%) of stage II; 83 cases (17.3%) of stage III ; IV stage 6 cases (1.3%).

[0059] The transcriptome data of 479 LUSC patients with lung squamous cell carcinoma who underwent surgery were extracted from the TCGA database to obtain the expression le...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a lung squamous cell carcinoma patient prognosis evaluation system based on CD47 and TIGIT double targets and application of the lung squamous cell carcinoma patient prognosis evaluation system. The invention also discloses an application of the substance for detecting the expression quantity of CD47 and TIGIT in any one of the following (A1)-(A6): (A1) preparing a product for prognosis evaluation of a lung squamous cell carcinoma patient; (A2) preparing a product for predicting the postoperative risk of the lung squamous cell carcinoma patient; (A3) preparing a product for predicting the total postoperative lifetime of the lung squamous cell carcinoma patient; (A4) prognosis evaluation of lung squamous cell carcinoma patients; (A5) predicting the postoperative risk of the lung squamous cell carcinoma patient; and (A6) predicting the total postoperative lifetime of the lung squamous cell carcinoma patient. According to the invention, a lung squamous cell carcinoma prognosis evaluation system based on CD47 and TIGIT double targets is constructed, and verification is carried out in a large-scale queue. Meanwhile, CD47 and TIGIT are potential immunotherapy targets for lung squamous cell carcinoma, and clear expression quantity provides a new method for predicting the curative effect of immunotherapy in the future while prognosis is evaluated.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and particularly relates to a lung squamous cell carcinoma patient prognosis evaluation system based on CD47 and TIGIT double targets and its application. Background technique [0002] Lung cancer is the cancer with the highest morbidity and mortality in my country. About 85% of them are non-small cell lung cancer (NSCLC), and lung squamous cell carcinoma (LUSC) accounts for about 25%-30% of NSCLC. Squamous cell carcinoma of the lung is common in men, elderly, and patients with a history of smoking, mainly in the central airway. The 5-year survival rate of patients with advanced squamous cell carcinoma of the lung is less than 20%. [0003] The prognosis of lung squamous cell carcinoma is related to a variety of factors, such as TNM (Tumor, Node, Metastasis) stage, tumor differentiation, etc. These factors are widely used to guide clinical decision-making. However, these factors are not su...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6886G01N33/574G16B30/10
CPCC12Q1/6886G01N33/57423G01N33/57484G16B30/10C12Q2600/158C12Q2600/118G01N2333/70503G01N2333/47
Inventor 杨震林徐佳晨彭岳陈颖
Owner CANCER INST & HOSPITAL CHINESE ACADEMY OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com